{
    "2020-01-16": [
        [
            {
                "time": "2020-01-01",
                "original_text": "Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 - CFO",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "quarterly deals",
                        "CFO"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2020-01-01",
                "original_text": "Eli Lilly (LLY) Gains But Lags Market: What You Should Know",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Gains",
                        "Lags Market"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-01-01",
                "original_text": "Lilly Confirms Date and Conference Call for Fourth-Quarter 2019 Financial Results Announcement",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Financial Results",
                        "Conference Call"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-01-01",
                "original_text": "FDA Risks Sacrificing Its Standards for Speed",
                "features": {
                    "keywords": [
                        "FDA",
                        "Standards",
                        "Speed"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "regulatory"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2020-01-01",
                "original_text": "J&J Seeks Label Expansion for Spravato Nasal Spray in EU",
                "features": {
                    "keywords": [
                        "J&J",
                        "Spravato",
                        "Label Expansion",
                        "EU"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2020-01-01",
                "original_text": "Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA",
                "features": {
                    "keywords": [
                        "Bristol-Myers",
                        "Opdivo-Yervoy",
                        "sBLA",
                        "NSCLC",
                        "FDA"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}